Following the company’s fourth quarter results, Raymond James analyst Rahul Sarugaser has chop... Read More
Forecasting a more gradual ramp up for its lead product, Stifel analyst Justin Keywood has trimmed h... Read More
The trend lines look great for HLS Therapeutics (HLS Therapeutics Stock Quote, Charts, News, Analyst... Read More
Clarus Securities analyst Noel Atkinson is sticking with a “Buy” rating on specialty pharma name... Read More
It’s been a rough ride these past two years for fans of specialty pharma company HLS Therapeutics ... Read More
Specialty pharma company HLS Therapeutics (HLS Therapeutics Stock Quote, Charts, News, Analysts, Fin... Read More
Following the company’s most recent quarterly results, Clarus Securities analyst Noel Atkinson... Read More
Investors should be gearing up for some movement in the biotech space, says iA Capital Markets analy... Read More
With the stock currently valued at less than half of what it was a year ago, something’s gotta giv... Read More
The trend lines are looking good for cardiovascular drug Vascepa, which should push shares higher fo... Read More
The Healthcare space has taken it on the chin this year, as stocks across the board are down by well... Read More
Look for a nice boost in second half revenues from pharma company HLS Therapeutics (HLS Therapeutics... Read More
The trend lines are looking good for Canadian specialty pharma company HLS Therapeutics (HLS Therape... Read More
Stifel GMP analyst Justin Keywood is encouraged by the progress from Canadian pharma name HLS Thera... Read More
Canadian specialty pharma company HLS Therapeutics (HLS Therapeutics Stock Quote, Chart, News, Anal... Read More
Rahul Sarugaser of Raymond James likes the story around HLS Therapeutics (HLS Therapeutics Stock Quo... Read More
It’s been an uncomfortable stretch for fans of Healthcare stocks, with names across the board losi... Read More
Noel Atkinson of Clarus Securities has dropped his target on Canadian specialty pharma company HLS ... Read More
Share
Tweet
pin
Share